Depré M - Search Results

1

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Van Hecken A, et al. Among authors: depre m. J Clin Pharmacol. 2000 Oct;40(10):1109-20. J Clin Pharmacol. 2000. PMID: 11028250 Clinical Trial.

2

Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers.

Van Hecken AM, Depré M, De Schepper PJ, Fowler PA, Lacey LF, Durham JM. Van Hecken AM, et al. Among authors: depre m. Br J Clin Pharmacol. 1992 Jul;34(1):82-4. doi: 10.1111/j.1365-2125.1992.tb04113.x. Br J Clin Pharmacol. 1992. PMID: 1321655 Free PMC article. Clinical Trial.

3

Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men.

Depré M, Meeter C, Van Hecken A, Laskin OL, Buntinx A, De Schepper PJ. Depré M, et al. Clin Pharmacol Ther. 1992 Oct;52(4):409-12. doi: 10.1038/clpt.1992.163. Clin Pharmacol Ther. 1992. PMID: 1424413 Clinical Trial.

4

Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.

Depré M, Margolskee DJ, Hsieh JY, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, De Schepper PJ. Depré M, et al. Eur J Clin Pharmacol. 1992;43(4):427-30. doi: 10.1007/BF02220621. Eur J Clin Pharmacol. 1992. PMID: 1451725 Clinical Trial.

5

Dose-dependent kinetics of the enantiomers of MK-571, and LTD4-receptor antagonist.

Depré M, Margolskee DJ, Van Hecken A, Hsieh JS, Buntinx A, De Schepper PJ, Rogers JD. Depré M, et al. Eur J Clin Pharmacol. 1992;43(4):431-3. doi: 10.1007/BF02220622. Eur J Clin Pharmacol. 1992. PMID: 1451726 Clinical Trial.

6

Tolerance and pharmacokinetics of propacetamol, a paracetamol formulation for intravenous use.

Depré M, van Hecken A, Verbesselt R, Tjandra-Maga TB, Gerin M, de Schepper PJ. Depré M, et al. Fundam Clin Pharmacol. 1992;6(6):259-62. doi: 10.1111/j.1472-8206.1992.tb00119.x. Fundam Clin Pharmacol. 1992. PMID: 1487229 Clinical Trial.

7

Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor.

Van Hecken A, Depre M, De Lepeleire I, Laskin O, Au T, Woolf E, Yeh KC, De Schepper PJ. Van Hecken A, et al. Among authors: depre m. Int J Clin Pharmacol Res. 1994;14(2):45-50. Int J Clin Pharmacol Res. 1994. PMID: 7530697 Clinical Trial.

8

Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.

Depré M, Friedman B, Van Hecken A, de Lepeleire I, Tanaka W, Dallob A, Shingo S, Porras A, Lin C, de Schepper PJ. Depré M, et al. Clin Pharmacol Ther. 1994 Jul;56(1):22-30. doi: 10.1038/clpt.1994.96. Clin Pharmacol Ther. 1994. PMID: 8033491 Clinical Trial.

9

Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5 alpha-reductase inhibitor, in healthy subjects.

Van Hecken A, Depré M, Schwartz JI, Tjandramaga TB, Winchell GA, De Lepeleire I, Ng J, De Schepper PJ. Van Hecken A, et al. Among authors: depre m. Eur J Clin Pharmacol. 1994;46(2):123-6. doi: 10.1007/BF00199874. Eur J Clin Pharmacol. 1994. PMID: 8039530

10

Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.

Van Hecken A, Verbesselt R, Depré M, Tjandramaga TB, Angehrn J, Cawello W, De Schepper PJ. Van Hecken A, et al. Among authors: depre m. Eur J Clin Pharmacol. 1993;45(3):291-3. doi: 10.1007/BF00315400. Eur J Clin Pharmacol. 1993. PMID: 8276058 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters